Lymphoplasmacytic Lymphoma Completed Phase 3 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0031072 (Lymphoplasmacytic Lymphoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00801281First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.Treatment